Business, Health Care

Merck presents promising new data for three investigational medicines from diverse and expansive oncology pipeline at ESMO Virtual Congress 2020

Researchers Share New Data for Vibostolimab (MK-7684), Merck’s Anti-TIGIT Therapy, as Monotherapy and in Combination With KEYTRUDA® (pembrolizumab); First-Time Results for First-in-Class MK-4830 (Anti-ILT4 Therapy); and Late-Breaking Data for MK-6482 (HIF-2α Inhibitor) Merck to Initiate Phase 3 Study of Vibostolimab in Non-Small

Business, Health Care, Local News

Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) demonstrates significant survival benefits in patients with advanced Renal Cell Carcinoma in pivotal Phase 3 CheckMate -9ER trial

Opdivo in combination with CABOMETYX showed superior overall survival and doubled median progression-free survival and objective response rate with a favorable safety profile vs. sunitinib Efficacy benefits were observed across key patient subgroups, including all International Metastatic Renal Cell Carcinoma Database Consortium

Business, Health Care

Merck’s KEYTRUDA® (pembrolizumab) reduced the risk of distant metastasis or death by 40% versus placebo as adjuvant treatment in resected, high-risk stage III melanoma

Long-Term Findings From EORTC1325/KEYNOTE-054 Show Adjuvant KEYTRUDA Demonstrated a Sustained Recurrence-Free Survival Benefit Versus Placebo Across Stage IIIA (>1 mm Lymph Node Metastasis), IIIB and IIIC Melanoma Merck Is Advancing a Broad Clinical Program Evaluating KEYTRUDA for the Early Treatment of Cancer

Business, Health Care

OncLive® names the 2020 class of Giants of Cancer Care®

Annual recognition program will honor 15 world-renowned leaders who have achieved landmark success within the global field of oncology CRANBURY, N.J.–(BUSINESS WIRE)–#Breast–OncLive®, the nation’s leading multimedia resource focused on providing oncology professionals with relevant, insightful information on patient care, is pleased to